Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
about
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical DataRole of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentMolecular pathways and targets in prostate cancerThe frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuseCompetition between serum IgG, IgM, and IgA anti-glycan antibodiesSignificant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum.ABO blood type correlates with survival on prostate cancer vaccine therapyDiverse molecular recognition properties of blood group A binding monoclonal antibodies.Biophysical characterization of lectin-glycan interactions for therapeutics, vaccines and targeted drug-delivery.Oncolytic virotherapy for urological cancers.Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins.Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins.A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma
P2860
Q26801501-BDA180D8-4A05-4E17-802F-E592E34AEC21Q33718182-824D8507-7495-4A8B-B175-EAE8DBA5F478Q34365632-DF747EC8-687A-489E-BAA5-2FB7F0A27AF0Q34476304-73E4CF66-0B85-45BB-9C6B-AC6A7F423242Q35217313-02B597D0-BF20-4C63-9482-4DBC8965E733Q36497647-D8DF3C0F-D87D-4E88-A26E-AF06617A3B5FQ36499916-CF4BE8C0-3576-450C-A6F6-0E2517E10DC3Q36544831-9C25D13A-AFE7-452A-85EA-3900674BC7DDQ36745220-0C35A99E-DDB3-4C0B-85A0-243889F37477Q38297149-6D4E27B2-91C1-460F-BBF8-6F56C75CD036Q38842126-5AD8A74E-A71B-4840-9CDE-BC5BCD490F57Q41238074-220C6F7D-A2C0-4857-A40C-43279933DF05Q46767596-131D2B76-2E0D-4F25-923E-9CB0473D2266Q49870857-769AFA63-910B-4166-91C9-90017E05E66DQ55026505-6FB48B2F-6CB8-4EEF-BA4B-844753A9DF78Q55026796-B41E010B-6C3F-4E55-981C-3954FDFB71AFQ59117175-057A177F-4DC8-40D9-BB09-EC5A0B5F5C7B
P2860
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@ast
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@en
type
label
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@ast
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@en
prefLabel
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@ast
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@en
P2093
P2860
P356
P1476
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
@en
P2093
Christopher T Campbell
James L Gulley
James W Hodge
Jeffrey Schlom
Oyindasola Oyelaran
P2860
P304
P356
10.1073/PNAS.1314722111
P407
P577
2014-04-14T00:00:00Z